8-K
filed May 5, 2026, 7:59 PM ET
ticker SYRE
CIK 0001636282
earnings
confidence high
sentiment positive
materiality 0.85
Spyre Q1 net loss $69M; SPY001 hits primary endpoint; cash runway to H2 2029
Spyre Therapeutics, Inc.
2026-Q1 EPS reported
-$0.74
- Net loss of $69.0M in Q1 2026 vs $44.8M in Q1 2025; R&D expenses $60.4M (up from $41.6M).
- Pro forma cash $1,176.8M as of March 31, 2026, including $435.3M net from April 2026 offering; runway into H2 2029.
- SPY001 achieved primary endpoint in Part A of SKYLINE: RHI score reduction 9.2 points (p<0.0001); clinical remission 40%, endoscopic improvement 51%.
- SPY001 safety consistent with α4β7 class; RA sub-study of SKYWAY over-enrolled, topline readout accelerated to Q3 2026.
- On track for 6 proof-of-concept readouts in 2026 across SKYLINE and SKYWAY Phase 2 trials.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001636282-26-000051
- form_type
- 8-K
- ticker
- SYRE
- cik
- 0001636282
- company_name
- Spyre Therapeutics, Inc.
- filed_at
- 2026-05-05T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:32.632570+00:00
- generated_at
- 2026-05-14T23:24:22.714697+00:00
- sec_items
- ["2.02", "9.01"]
- event_type
- earnings
- sentiment
- positive
- materiality_score
- 0.85
- calibrated_materiality_score
- 0.85
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001636282-26-000051
- json_url
- https://secwatch.observer/filing/0001636282-26-000051.json
- markdown_url
- https://secwatch.observer/filing/0001636282-26-000051.md
- text_url
- https://secwatch.observer/filing/0001636282-26-000051.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1636282/000163628226000051/0001636282-26-000051-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1636282/000163628226000051/syre-20260505.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
HPE
HPE Q2 FY26: record revenue $10.7B (+40%), raises FY26 guidance, introduces FY27 framework
Hewlett Packard Enterprise Co
June 1, 2026, 4:09 PM ET
earnings
Items 1.01, 2.02, 5.02, 7.01, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
On May 5, 2026, Spyre Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026.
Comparable filing
gross margin, and non-GAAP diluted net EPS, as well as its highest-ever free cash flow generation for a second quarter. Second Quarter Fiscal 2026 Financial Results • Revenue : $10.7 billion, up 40% from the prior-year period • Gross margins : ◦ GAAP of 36.5%, up 810 basis points from the prior-year period and up 60 basis points sequentially ◦ Non-GAAP (1) of 36.9%,
Filing page
SEC filing
CRDO
Credo Q4 revenue $437M (+157% YoY); guides Q1 $465-475M; CEO awarded 1.44M performance-based RSUs
Credo Technology Group Holding Ltd
June 1, 2026, 4:08 PM ET
earnings
Items 2.02, 5.02, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
On May 5, 2026, Spyre Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026.
Comparable filing
On June 1, 2026, Credo Technology Group Holding Ltd (the "Company") issued a press release announcing its financial results for the fiscal year ended May 2, 2026.
Filing page
SEC filing
URG
Ur-Energy Q1 2026: pounds captured up 41% QoQ, avg price $70.98, Shirley Basin commenced
UR-ENERGY INC
May 11, 2026, 7:59 PM ET
earnings
Items 2.02, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
On May 5, 2026, Spyre Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026.
Comparable filing
a 14% increase over Q4 2025 and a 13% increase over Q1 2025. Financial Performance ◾ Contracted Sales: We sold 55,000 produced pounds of U 3 O 8 as anticipated, generating $3.9 million in revenue, with a majority of our 2026 deliveries scheduled for the latter part of the year to complement the ramp-up and start-up schedules of Lost Creek and Shirley Basin. ◾
Filing page
SEC filing
ACH
Accendra Health Q1 revenue $627.8M, adj. EBITDA $58.4M; >$1.5B debt optimization
ACCENDRA HEALTH INC/VA/
May 11, 2026, 7:59 PM ET
earnings
Items 2.02, 7.01, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
On May 5, 2026, Spyre Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026.
Comparable filing
Commission this morning. Details on First Quarter 2026 Results First Quarter Results (1) ($ in millions, except per share data) 1Q26 1Q25 Net Revenue $ 627.8 $ 673.9 Loss from continuing operations, net of tax, GAAP $ (6.5) $ (3.8) Adj. net (loss) income from continuing operations, Non-GAAP $ (3.1) $ 23.2
Filing page
SEC filing
LQDA
Liquidia Q1 2026 net income $53M vs $38M loss YoY; YUTREPIA sales $130M
Liquidia Corp
May 11, 2026, 7:59 PM ET
earnings
Items 2.02, 8.01, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
On May 5, 2026, Spyre Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026.
Comparable filing
First Quarter 2026 Financial Results YUTREPIA sales led to the company’s third consecutive quarter of profitability with net income of $52.9 million and positive non-GAAP adjusted EBITDA of $71.2 million in the first quarter of 2026. Cash and cash equivalents totaled $222.8 million as of March 31, 2026, compared to $190.7 million as of December 31, 2025. Product sales, net, were $129.9 million for the three months ended March 31, 2026.
Filing page
SEC filing
TH
Target Hospitality Q1 revenue up 4% but net loss widens to $13M; announces $750M AI infrastructure contract
Target Hospitality Corp.
May 11, 2026, 7:59 PM ET
earnings
Items 2.02, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
On May 5, 2026, Spyre Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026.
Comparable filing
today reported results for the three months ended March 31, 2026. Financial Highlights for the quarter ended March 31, 2026 ● Revenue of $72.8 million. ● Net loss of ($13.0) million. ● Basic and diluted loss per share of $0.13 . ● Adjusted EBITDA (1) of $9.9 million. ● Net Cash Provided by Operating Activities of $7.0 million and Discretionary Cash
Filing page
SEC filing
FSK
FSK posts Q1 GAAP loss of $1.57/sh, NAV falls to $18.83; announces $150M preferred, tender, buyback
FS KKR Capital Corp
May 11, 2026, 7:59 PM ET
earnings
Items 1.01, 2.02, 7.01, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
On May 5, 2026, Spyre Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026.
Comparable filing
Earnings (Loss) per share of ($1.57), compared to Earnings (Loss) per share of ($0.41) for the quarter ended December 31, 2025
Filing page
SEC filing
VFF
Village Farms Q1 net income $2.9M; international export sales up 171%, adj. EBITDA +118%
Village Farms International, Inc.
May 11, 2026, 7:59 PM ET
earnings
Items 2.02, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
On May 5, 2026, Spyre Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026.
Comparable filing
Position with World’s Largest EU-GMP Certified Cannabis Facility; International Export Sales Grew 171% as Demand Continues to Increase • Consolidated Net Sales Increased 27% to $50.2 Million with Net Income of $2.9 Million or $0.03 Per Share • Adjusted EBITDA from Continuing Operations Increased 118% to $9.9 Million or 20% of Sales • Netherlands and Canadian
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.